[1] Gnjatic S,Bronte V,Brunet LR,et al.Identifying baseline immune-related biomarkers to predict clinical outcome of immunothera-py[J].J Immunother Cancer,2017,5:44.
[2] Hsiao YW,Chiu LT,Chen CH,et al.Tumor-infiltrating leukocyte composition and prognostic power in hepatitis B- and hepatitis C-related hepatocellular carcinomas[J].Genes (Basel),2019,10(8):630.
[3] Jiang Y,Han QJ,Zhang J.Hepatocellular carcinoma: Mechanisms of progression and immunotherapy[J].World J Gastroenterol,2019,25(25):3151-3167.
[4] Juengpanich S,Shi L,Iranmanesh Y,et al.The role of natural killer cells in hepatocellular carcinoma development and treatment: A narrative review[J].Transl Oncol,2019,12(8):1092-1107.
[5] Mossanen JC,Tacke F.Role of lymphocytes in liver cancer[J].Oncoimmunology,2013,2(11):e26468.
[6] Weiskirchen R,Tacke F.Immune surveillance of liver cancer in non-alcoholic fatty liver disease: excess lipids cause CD4 T-cells loss and promote hepatocellular carcinoma development[J].Hepatobiliary Surg Nutr,2016,5(5):433-437.
[7] Wu S,Yang W,Zhang H,et al.The prognostic landscape of tumor-infiltrating immune cells and immune checkpoints in glioblasto-ma[J].Technol Cancer Res Treat,2019,1(18):1533033819869949.
[8] Shirabe K,Motomura T,Muto J,et al.Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical manageme-nt[J].Int J Clin Oncol,2010,15(6):552-558.
[9] Schreiber RD,Old LJ,Smyth MJ.Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion[J].Science,2011,331(6024):1565-1570.
[10] Ding W,Xu X,Qian Y,et al.Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: A meta-analysis[J].Medicine (Baltimore),2018,97(50):e13301.
[11] Kang HJ,Oh JH,Chun SM,et al.Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes[J].J Hepatol,2019,71(1):91-103.
[12] Newman AM,Liu CL,Green MR,et al.Robust enumeration of cell subsets from tissue expression profiles[J].Nat Methods,2015,12(5):453-457.
[13] Rohr-Udilova N,Klinglmuller F,Schulte-Hermann R,et al.Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma[J].Sci Rep,2018,8(1):6220.
[14] Li W,Xu L,Han J,et al.Identification and validation of tumor stromal immunotype in patients with hepatocellular carcinoma[J].Front Oncol,2019,9:664.
[15] Cerami E,Gao J,Dogrusoz U,et al.The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J].Cancer Discov,2012,2(5):401-404.
[16] Gao J,Aksoy BA,Dogrusoz U,et al.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J].Sci Signal,2013,6(269):pl1.
[17] Ruffell B,Coussens LM.Macrophages and therapeutic resistance in cancer[J].Cancer Cell,2015,27(4):462-472.
[18] Noy R,Pollard JW.Tumor-associated macrophages: from mechanisms to therapy[J].Immunity,2014,41(1):49-61.
[19] Mantovani A,Sozzani S,Locati M,et al.Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes[J].Trends Immunol,2002,23(11):549-555.
[20] Yeung OW,Lo CM,Ling CC,et al.Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma[J].J Hepatol,2015,62(3):607-616.
[21] Zhang J,Chang L,Zhang X,et al.Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in hepatocellular carcinoma[J].J Invest Surg,2019:1-10.
[22] Li JQ,Yu XJ,Wang YC,et al.Distinct patterns and prognostic values of tumor-infiltrating macrophages in hepatocellular carcinoma and gastric cancer[J].J Transl Med,2017,15(1):37.
[23] Ding T,Xu J,Wang F,et al.High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection[J].Hum Pathol,2009,40(3):381-389.
[24] Li YW,Qiu SJ,Fan J,et al.Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resecti-on[J].J Cancer Res Clin Oncol,2009,135(3):439-449.
[25] Minami K,Hiwatashi K,Ueno S,et al.Prognostic significance of CD68,CD163 and Folate receptor-beta positive macrophages in hepatocellular carcinoma[J].Exp Ther Med,2018,15(5):4465-4476.
[26] Dong P,Ma L,Liu L,et al.CD86(+)/CD206(+),diametrically polarized tumor-associated macrophages,predict hepatocellular carcinoma patient prognosis[J].Int J Mol Sci,2016,17(3):320.
[27] Zhou J,Ding T,Pan W,et al.Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients[J].Int J Cancer,2009,125(7):1640-1648.
[28] O'Rourke JM,Patten DA,Shetty S.Tumour-associated macrophages in hepatocellular carcinoma: Pressing the metabolic switch to prevent T cell responses[J].J Hepatol,2019,71(2):243-245.
[29] Ostuni R,Kratochvill F,Murray PJ,et al.Macrophages and cancer: from mechanisms to therapeutic implications[J].Trends Immunol,2015,36(4):229-239.
[30] Mills CD,Lenz LL,Harris RA.A Breakthrough: Macrophage-directed cancer immunotherapy[J].Cancer Res,2016,76(3):513-516.
[31] Degroote H,Van Dierendonck A,Geerts A,et al. Preclinical and clinical therapeutic strategies affecting tumor-associated macrophages in hepatocellular carcinoma[J].J Immunol Res,2018,2018:7819520.
[32] Murdoch C,Muthana M,Coffelt SB,et al.The role of myeloid cells in the promotion of tumour angiogenesis[J].Nat Rev Cancer,2008,8(8):618-631.
[33] Fujita N,Nishie A,Aishima S,et al.Role of tumor-associated macrophages in the angiogenesis of well-differentiated hepatocellular carcinoma: pathological-radiological correlation[J].Oncol Rep,2014,31(6):2499-2505.
[34] Peng SH,Deng H,Yang JF,et al.Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues[J].World J Gastroenterol,2005,11(41):6521-6524.
[35] Fu XT,Dai Z,Song K,et al.Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway[J].Int J Oncol,2015,46(2):587-596.